BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 21314247)

  • 1. Incidence of neutropenia, chemotherapy delivery, and use of colony-stimulating factor in patients with non-Hodgkin lymphoma of different age groups.
    Pettengell R; Schwenkglenks M
    Leuk Lymphoma; 2011 Jun; 52(6):1133-6. PubMed ID: 21314247
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
    Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U
    Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma.
    Lyman GH; Delgado DJ
    Cancer; 2003 Dec; 98(11):2402-9. PubMed ID: 14635075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study.
    Pettengell R; Bosly A; Szucs TD; Jackisch C; Leonard R; Paridaens R; Constenla M; Schwenkglenks M;
    Br J Haematol; 2009 Mar; 144(5):677-85. PubMed ID: 19055662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary prophylaxis with granulocyte colony-stimulating factor (GCSF) reduces the incidence of febrile neutropenia in patients with non-Hodgkin lymphoma (NHL) receiving CHOP chemotherapy treatment without adversely affecting their quality of life: cost-benefit and quality of life analysis.
    Lee S; Knox A; Zeng IS; Coomarasamy C; Blacklock H; Issa S
    Support Care Cancer; 2013 Mar; 21(3):841-6. PubMed ID: 22972488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of age and colony-stimulating factor use on hospital length of stay for febrile neutropenia in CHOP-treated non-Hodgkin's lymphoma.
    Chrischilles E; Delgado DJ; Stolshek BS; Lawless G; Fridman M; Carter WB
    Cancer Control; 2002; 9(3):203-11. PubMed ID: 12060818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma.
    Intragumtornchai T; Sutheesophon J; Sutcharitchan P; Swasdikul D
    Leuk Lymphoma; 2000 Apr; 37(3-4):351-60. PubMed ID: 10752986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma.
    Grigg A; Solal-Celigny P; Hoskin P; Taylor K; McMillan A; Forstpointner R; Bacon P; Renwick J; Hiddemann W;
    Leuk Lymphoma; 2003 Sep; 44(9):1503-8. PubMed ID: 14565651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: a risk factor analysis.
    Morrison VA; Picozzi V; Scott S; Pohlman B; Dickman E; Lee M; Lawless G; Kerr R; Caggiano V; Delgado D; Fridman M; Ford J; Carter WB;
    Clin Lymphoma; 2001 Jun; 2(1):47-56. PubMed ID: 11707870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced-dose (two-thirds) R-CHOP chemotherapy for elderly patients with non-Hodgkin lymphoma.
    Kikuchi M; Nakasone H; Akahoshi Y; Nakano H; Ugai T; Wada H; Yamasaki R; Sakamoto K; Kawamura K; Ishihara Y; Sato M; Ashizawa M; Terasako-Saito K; Kimura S; Yamazaki R; Kako S; Kanda J; Nishida J; Sekiguchi N; Noto S; Kida M; Hangaishi A; Usuki K; Kanda Y
    J Chemother; 2015 Feb; 27(2):99-105. PubMed ID: 25314911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human immunodeficiency virus-associated diffuse non-Hodgkin's lymphoma in Venezuelan patients: treatment with full-dose cyclophosphamide-doxorubicin-vincristine-prednisone without routine use of granulocyte-colony stimulating factor.
    Hernàndez DE; Hernàndez AE
    Eur J Cancer Care (Engl); 2006 Dec; 15(5):493-6. PubMed ID: 17177909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab-associated neutropenia.
    Dunleavy K; Tay K; Wilson WH
    Semin Hematol; 2010 Apr; 47(2):180-6. PubMed ID: 20350665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A long-term follow-up study of prospective 80%-dose CHOP followed by involved-field radiotherapy in elderly lymphoma patients.
    Shikama N; Oguchi M; Isobe K; Nakamura K; Tamaki Y; Hasegawa M; Kodaira T; Sasaki S; Kagami Y;
    Jpn J Clin Oncol; 2011 Jun; 41(6):764-9. PubMed ID: 21459892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin's lymphoma.
    Picozzi VJ; Pohlman BL; Morrison VA; Lawless GD; Lee MW; Kerr RO; Ford JM; Delgado DJ; Fridman M; Carter WB
    Oncology (Williston Park); 2001 Oct; 15(10):1296-306; discussion 1310-1, 1314. PubMed ID: 11702959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Full-dose chemotherapy for non-Hodgkin's lymphoma in the elderly. Dutch Hematology-Oncology in Adults Study Group.
    Sonneveld P; Hop W; Mulder AH; Michiels JJ; Blijham G; van de Lelie J; Raemakers JW; Nieuwenhuis K; van der Heul C
    Semin Hematol; 1994 Apr; 31(2 Suppl 3):9-12. PubMed ID: 8073309
    [No Abstract]   [Full Text] [Related]  

  • 16. Increasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin's lymphoma.
    Blayney DW; McGuire BW; Cruickshank SE; Johnson DH
    Oncologist; 2005 Feb; 10(2):138-49. PubMed ID: 15709216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of interstitial pneumonitis in non-Hodgkin's lymphoma patients receiving immunochemotherapy with pegylated liposomal doxorubicin and rituximab.
    Zhou T; Shen Q; Peng H; Chao T; Zhang L; Huang L; Yang K; Thapa S; Yu S; Jiang Y
    Ann Hematol; 2018 Jan; 97(1):141-147. PubMed ID: 29086009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of chemotherapy-induced neutropenia using G-CSF with VACOP-B--a case report.
    Anglin P; Strauss BA; Brandwein JM
    Leuk Lymphoma; 1993 Nov; 11(5-6):469-72. PubMed ID: 7510192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Supportive care for patients with non-Hodgkin lymphoma receiving R-CHOP chemotherapy].
    Kato H
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():636-41. PubMed ID: 25831838
    [No Abstract]   [Full Text] [Related]  

  • 20. Cyclophosphamide, pegylated liposomal doxorubicin, vincristine and prednisone (CDOP) plus rituximab is effective and well tolerated in poor performance status elderly patients with non-Hodgkin's lymphoma.
    Visani G; Guiducci B; D'Adamo F; Mele A; Nicolini G; Leopardi G; Sparaventi G; Barulli S; Malerba L; Isidori A; Malagola M; Piccaluga PP
    Leuk Lymphoma; 2005 Mar; 46(3):477-9. PubMed ID: 15621843
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.